Day 162, the firm landed two major cases on the sa day.
Harvey's announcent ca first, loud enough for the entire bullpen to hear.
"Corporate espionage lawsuit. Forr CTO of a Fortune 500 company allegedly stole trade secrets, started competing firm. Two hundred million in damages. Public trial. Mike's lead associate."
Applause from the associates. Mike looked excited and terrified.
Two hours later, Louis appeared at my desk.
"Pharmaceutical rger. Three companies consolidating—Cordova, BioDyne, and a European manufacturer. FDA approval required, EU competition law compliance, international regulatory coordination. Eight weeks to close or the deal collapses. You're running point."
No applause. No audience. Just work.
[WIN RATE CALCULATOR: INITIAL ASSESSNT]
[SUCCESSFUL RGER PROBABILITY: 61% (±14%)]
[COMPLEXITY: EXTRE - MULTI-JURISDICTION REGULATORY APPROVAL]
[TILINE: AGGRESSIVE - 8 WEEKS]
[VARIABLES: FDA PRE-RGER REVIEW, EU COMPETITION LAW, IP TRANSFER COMPLICATIONS, EMPLOYEE STOCK OPTIONS ACROSS 400 EMPLOYEES]
"When do we start?"
"Now."
Days 163 through 168 blurred into regulatory filings, conference calls across ti zones, and System-enhanced docunt analysis.
I coordinated with three separate legal teams—Cordova's internal counsel, BioDyne's outside firm, and the European manufacturer's German attorneys who spoke perfect English but thought in a completely different legal frawork.
FDA pre-rger approval required demonstrating the consolidation wouldn't reduce competition in critical drug markets. I built competitive analysis showing eight other manufacturers in each therapeutic area, sufficient competition remaining post-rger.
EU competition law demanded proof the rger wouldn't create market dominance. Different standard, different evidence, sa goal—convince regulators this was pro-competitive consolidation, not anti-competitive monopolization.
[WIN RATE CALCULATOR: CONTINUOUS UPDATES]
[DAY 163: 61% SUCCESS PROBABILITY]
[DAY 165: 67% (FDA INITIAL APPROVAL)]
[DAY 167: 71% (EU PRELIMINARY CLEARANCE)]
[PROJECTING: 73% FINAL SUCCESS IF CURRENT TRAJECTORY MAINTAINED]
IP transfer was the nightmare scenario—patents held across three jurisdictions, licensing agreents that contradicted each other, technology sharing arrangents that created circular dependencies.
I spent eighteen hours on Day 166 untangling the patent portfolio, creating a unified IP structure that satisfied all three companies' concerns while maintaining regulatory compliance.
Employee stock options for 400 employees across five countries required converting three different equity structures into one, preserving value while deferring tax consequences.
[ARGUNT CRUSHER: REGULATORY OBJECTION PREPARATION]
[POTENTIAL FDA CONCERN: MARKET CONCENTRATION IN ONCOLOGY DRUGS]
[COUNTER: EIGHT REMAINING COMPETITORS, INCREASED R&D INVESTNT]
[POTENTIAL EU CONCERN: TRANSFER PRICING MANIPULATION]
[COUNTER: THIRD-PARTY COMPARABLE PRICING, ARM'S LENGTH TRANSACTIONS]
anwhile, Harvey's espionage trial proceeded with dia fanfare.
News coverage. Courthouse steps interviews. Dramatic witness testimony.
Mike was learning to perform. I was learning to execute.
Different skills. Both valuable.
Day 170, both cases resolved.
Harvey's trial settled at $187 million—client wanted $200 million, but settlent avoided appeal risk and guaranteed paynt within sixty days.
Firm-wide celebration. Newsletter feature with photos. Harvey's victory speech about "tireless advocacy and courtroom excellence."
My rger closed at 4:47 PM.
All regulatory approvals secured. Three companies now unified. Zero complications. Zero dia coverage.
Financial impact: Harvey's case generated $4.5 million in fees.
Louis's rger generated $6.2 million in fees plus ongoing relationship with the consolidated pharmaceutical company worth another $300,000 annually.
At the evening reception celebrating Harvey's victory, Louis pulled aside.
"You and I need to talk about compensation."
"What?"
"You just ran a rger that generated more revenue than Harvey's trial. As an associate. That deserves recognition."
"I was doing my job."
"You were doing partner-level work. There's a difference."
Louis raised his voice slightly, addressing the associates nearby.
"Scott Roden deserves recognition for exceptional execution on highly complex technical work. The pharmaceutical rger closed flawlessly due to his efforts."
Polite applause. Nothing like Harvey's reception, but genuine.
Mike approached afterward.
"Heard your rger was technically impressive."
"Heard your trial was dramatic."
"Different kinds of law."
"Different kinds of lawyers. Both needed."
Mike nodded, understanding the implicit recognition that we weren't competing directly because we were playing different gas entirely.
Donna found near the exit.
"You and Louis make a good team."
"We complent each other. He handles relationships and negotiations. I handle structure and execution."
"That's partnership dynamics. You've essentially built a junior partnership with Louis."
The observation stopped .
She's right. I'm not just Louis's associate anymore. I'm his strategic partner.
Ten months in, and I've built sothing that looks like a practice.
We left together, and Harvey watched from across the room—expression calculating, asuring, evaluating.
He sees it too. I'm not just an associate anymore.
That's either very good or very dangerous.
Probably both.
MORE POWER STONES And REVIEWS== MORE CHAPTERS
To supporting in Pateron .
with exclusive access to more chapters (based on tiers more chapters for each tiers) on my Patreon, you get more chapters if you ask for more (in few days), plus new fanfic every week! Your support starting at just $6/month helps keep crafting the stories you love across epic universes like [ In The Witcher With Avatar Powers,In The Vikings With Deja Vu System,Stranger Things Demogorgon Tar ...].
By joining, you're not just getting more chapters—you're helping bring new worlds, twists, and adventures to life. Every pledge makes a huge difference!
👉 Join now at patreon/TheFinex5 and start reading today!
User Comments
0 comments from readers